XRCC2 and non-small cell lung carcinoma: Niraparib treatment had no effect on the growth of the three BRCAWT, ATMWT NSCLC PDX models that contained a biallelic deleterious mutation in either RAD51B, RAD51D, or XRCC2 (0%–20% TGI, Figure 5A).